Skip to main content
Antibiotics logoLink to Antibiotics
. 2022 Oct 30;11(11):1515. doi: 10.3390/antibiotics11111515

Imidazothiazole Derivatives Exhibited Potent Effects against Brain-Eating Amoebae

Ruqaiyyah Siddiqui 1,2, Mohammed I El-Gamal 3,4,5,*,, Anania Boghossian 1, Balsam Qubais Saeed 4,6, Chang-Hyun Oh 7,8, Mohammed S Abdel-Maksoud 9, Ahmad M Alharbi 10, Hasan Alfahemi 11, Naveed Ahmed Khan 2,6,*
Editor: Carlos M Franco
PMCID: PMC9686523  PMID: 36358170

Abstract

Naegleria fowleri (N. fowleri) is a free-living, unicellular, opportunistic protist responsible for the fatal central nervous system infection, primary amoebic meningoencephalitis (PAM). Given the increase in temperatures due to global warming and climate change, it is estimated that the cases of PAM are on the rise. However, there is a current lack of awareness and effective drugs, meaning there is an urgent need to develop new therapeutic drugs. In this study, the target compounds were synthesized and tested for their anti-amoebic properties against N. fowleri. Most compounds exhibited significant amoebicidal effects against N. fowleri; for example, 1h, 1j, and 1q reduced N. fowleri’s viability to 15.14%, 17.45% and 28.78%, respectively. Furthermore, the majority of the compounds showed reductions in amoeba-mediated host death. Of interest are the compounds 1f, 1k, and 1v, as they were capable of reducing the amoeba-mediated host cell death to 52.3%, 51%, and 56.9% from 100%, respectively. Additionally, these compounds exhibit amoebicidal properties as well; they were found to decrease N. fowleri’s viability to 26.41%, 27.39%, and 24.13% from 100%, respectively. Moreover, the MIC50 values for 1e, 1f, and 1h were determined to be 48.45 µM, 60.87 µM, and 50.96 µM, respectively. Additionally, the majority of compounds were found to exhibit limited cytotoxicity, except for 1l, 1o, 1p, 1m, 1c, 1b, 1zb, 1z, 1y, and 1x, which exhibited negligible toxicity. It is anticipated that these compounds may be developed further as effective treatments against these devastating infections due to brain-eating amoebae.

Keywords: Naegleria fowleri, amoebicidal, anti-amoebic, mortality, cytotoxicity, cytopathogenicity

1. Introduction

Naegleria fowleri (N. fowleri) is a free-living protist of the Heterolobosea class; it is responsible for a fatal central nervous infection (CNS) known as primary amoebic meningoencephalitis (PAM); hence, it has been given the name brain-eating amoeba [1,2,3,4]. This amoeba is distributed across every continent except Antarctica [1]. The presence of N. fowleri in water makes individuals pursuing water related activities more susceptible; activities such as swimming, diving, water skiing, nasal cleansing, and the performance of ritual ablutions all increase the susceptibility of encountering N. fowleri [5,6,7]. Once encountered, an individual may obtain the CNS infection PAM, with a mortality rate exceeding 90%; this infection is not limited to immuno-compromised patients only, but immuno-competent patients may also come across it [6,8,9,10,11,12,13,14]. Unfortunately, as temperatures are on a rise due to global warming, meaning extremely hot summers are more frequent, an increase in the number of encephalitis cases has been found; in fact, the number of reported cases of PAM has increased globally [2,6,7,15,16].

Making matters worse is the lack of effective medications and awareness towards this free-living amoeba [15]. The drug of choice toward the treatment of PAM is the anti-fungal amphotericin B [1,10,15,17,18,19]. Amphotericin B is believed to alter the membrane permeability by binding to ergosterol within the cell membrane and to create pores, leading to the cell death [1,10]. However, amphotericin B has been associated with nephrotoxicity, as a high concentration of it is necessary in order to pass through the blood–brain barrier; hence, the development of new and safe drugs is necessary [10,12,15,19]. In this study, a series of imidazothiazole derivatives previously reported as antiproliferative agents were tested against N. fowleri for their anti-amoebic, cytotoxic, and cytopathogenic properties.

We previously reported a series of imidazo[2,1-b]thiazole derivatives as anti-proliferative candidates against melanoma, as well as other types of cancer [20,21,22,23,24]. They act via the inhibition of RAF kinases, including V600E-B-RAF and C-RAF. They are able to penetrate the cell membrane and inhibit the kinase inside melanoma cells. In addition, this series of compounds showed promising anti-amoebic activity against Acanthamoeba castellanii [25]. This encouraged us to extend our anti-amoebic investigations of the compounds with the hope of finding promising leads. Therefore, we decided to test their anti-amoebic activity against N. fowleri based on their cell-membrane-penetrant properties.

2. Results

2.1. Majority of Compounds Exhibited Significant Amoebicidal Properties against Naegleria fowleri

The antiamoebic properties of the compounds against N. fowleri were determined through amoebicidal assays. After the incubation of N. fowleri with 50 µM of the compounds, the amoebicidal activity levels of the compounds were recorded, and those exhibiting significant activity were determined. According to the results obtained, most compounds showed statistically significant amoebicidal properties (t-test, two-tailed distribution, p ≤ 0.05); of the various compounds tested, only the compounds 1n and 1w exhibited no significant effect (Figure 1), whereas 1a, 1d, 1e, 1i, 1f, 1g, 1h, 1j, 1k, 1l, 1o, 1p, 1q, 1r, 1s, 1t, 1v, 1zc, 1zd, 1m, 1c, 1b, 1zb, 1z, 1y, 1za, and 1x decreased the amoeba’s viability significantly from 100% to 55.12%, 34.84%, 23.46%, 44.21, 26.41%, 42.94%, 15.14%, 17.45%, 27.39%, 37.75%, 33.97%, 41.77%, 28.78%, 45.23%, 38.29%, 35.54%, 24.13%, 41.31%, 25.54%, 57.28%, 60.64%,79.72%, 54.45%, 71.91%, 25.08%, 50.59%, and 27.82%, respectively (Figure 1).

Figure 1.

Figure 1

The majority of drugs exhibited significant amoebicidal properties against Naegleria fowleri. Significant anti-amoebic effects were found for the majority of compounds against N. fowleri after a 24 h incubation period. The data are illustrative of independent experiments performed and are presented with a mean ± standard error. Furthermore, the p-values were determined through the conduction of a two-sample t-test with two-tailed distributions (* is ≤ 0.05).

Additionally, the minimum inhibitory concentrations required to inhibit 50% of N. fowleri growth (MIC50) of compounds for 1e, 1f, and 1h were determined through the conduction of amoebicidal assays at concentrations of 25 µM, 50 µM, and 75 µM (Table 1). According to the results obtained, at concentrations of 50.96 µM, 60.87 µM, and 48.45 µM, compounds 1e, 1h, and 1f are capable of inhibiting 50% of N. fowleri growth (Table 1).

Table 1.

The MIC50 values of the compounds against N. fowleri were determined for the various compounds against N. fowleri. Concentrations of 25 µM, 50 µM, and 75 µM were tested.

Naegleria fowleri
25 µM 50 µM 75 µM MIC50
Amoeba Alone 100
1e 93 ± 9.7 52.16 ± 1.7 19 ± 1.7 50.96
1f 99 ± 7.3 44 ± 3.9 17 ± 4.4 48.45
1h 96 ± 8.5 73 ± 2.4 26 ± 0.8 60.87

2.2. Compounds Exhibited Limited Cytotoxicity against Human Cell Lines

The toxicity levels of the compounds against human cells were determined through the conduction of LDH assays. As per ISO 10993-5, if 80% of the cells are viable, the compounds are considered to be non-toxic, whereas if the cell viability is between 40% and 60%, the compounds are considered to be weakly toxic [26,27]. Hence, the compounds 1r, 1s, 1t, 1zc, 1q, 1n, 1a, 1h, 1i, 1f, 1g, 1e, 1j, 1d, 1k, 1v, 1za, 1w, and 1zd exhibited limited cytotoxicity against human cells, as they were found to exhibit 26.5%, 25.3%, 26.1%, 30.1%, 37.4%, 20.8%, 34.4%, 22.4%, 21.7%, 33.6%, 25.1%, 26.1%, 33.3%, 22%, 34.1%, 25.1%, 21.8%, 24.9%, and 36.1% cell viability, respectively (Figure 2). The compounds 1o, 1l, 1p, 1m, 1c, 1b, 1zb, 1z, 1y, and 1x were found to be non-toxic, possessing minimal toxicity at 15.4%, 17.2%, 19.1%, 17.5%, 5.3%, 7.9%, 13.5%, 2.2%, 0.8%, 1.5%, and 2.2%, respectively (Figure 2).

Figure 2.

Figure 2

The majority of compounds exhibited minimal cytotoxicity against human cell lines. Confluent monolayers of HeLa cells were treated with 50 µM of the compounds. The compounds 1o, 1l, 1p, 1m, 1c, 1b, 1zb, 1z, 1y, and 1x were non-toxic, whereas the compounds 1r, 1s, 1t, 1zc, 1q, 1n, 1a, 1h, 1i, 1f, 1g, 1e, 1j, 1d, 1k, 1v, 1za, 1w, and 1zd exhibited limited cytotoxicity against human cells.

2.3. Majority of Compounds Resulted in Decreased in Amoeba-Mediated Cytotoxic Activity against Human Cells

The amoeba-mediated host cell death was determined through cytopathogenicity assays. Upon the pre-treatment of N. fowleri with compounds 1r, 1s, 1t, 1zc, 1n, 1a, 1h, 1i, 1f, 1g, 1e, 1j, 1d, 1k, 1v, 1za, 1l, 1p, 1m, 1c, 1b, 1zb, 1z, 1y, and 1x, reductions in amoeba-mediated cell toxicity were found. The compounds reduced the toxicity of N. fowleri against human cells from 100% to 49.8%, 63.2%, 85.7%, 51.6%, 60.4%, 60.4%, 64.5%, 59.8%, 52.3%, 50.1%, 65.8%, 77.8%, 48.5%, 51%, 56.9%, 78.5%, 70.8%, 83.5%, 31.6%, 29.8%, 75.7%, 35.9%, 35.9%, 36.1%, and 39.4%, respectively (Figure 3).

Figure 3.

Figure 3

The majority of compounds resulted in decrease in amoeba-mediated cytotoxic activity against human cells. Here, 50 µM of the compounds reduced the Naegleria fowleri-mediated cytotoxicity against human cells; 2 × 105 N. fowleri cells were incubated with 50 µM of the compound for 2 h. Following the incubation period, the pre-treated were amoebae placed on HeLa cell monolayers and incubated overnight. It was found that some of the compounds were capable of inhibiting the amoeba-meditated host cytotoxicity. * Significant reduction in amoeba-mediated cytotoxicity compared to the untreated amoeba + cells.

3. Discussion

N. fowleri is a free-living, unicellular, eukaryotic protist found across the environment [14,28,29,30,31]. This amoeba is responsible for the fatal CNS infection PAM, which has a mortality rate exceeding 90% [29,31,32,33]. Making matters worse are the increasing temperatures due to global warming, as this amoeba prefers warmer temperatures [7,15]. Additionally, individuals pursuing water-related activities such as diving, swimming, nasal cleansing, and ritual ablutions are more susceptible to encountering this amoeba and being infected [6,7]. However, no effective treatment is available, as the drug of choice for the treatment of PAM is amphotericin B, which needs to be administered in high doses to be able to pass the blood–brain barrier, meaning side effects such as nephrotoxicity may result [15,17,18,19].

As the search for safer and improved treatments against N. fowleri infection continue, various studies have been conducted. For example, recent studies involved the conjugation of silver and gold nanoparticles with various drugs to enhance their efficacy, with the aim of enhancing the efficacy of the available treatments [11,15,33]. Another study observed the effect of cholesterol-lowering statins against N. fowleri [34]. Pavastatin was found to show potent amoebicidal activity against N. fowleri strains [34].

In this study, the tested synthetic compounds were hypothesized to show significant anti-amoebic properties. The anti-amoebic properties of the compounds were determined through the conduction of amoebicidal and cytopathogenicity assays; furthermore, the safety of the compounds against human cells was determined through the conduction of lactate dehydrogenase assays through which the cell cytotoxicity levels of the compounds were determined. Of interest are the compounds 1k, 1f, and 1v, as they are capable of reducing amoeba-mediated host cell death to 51%, 52.3%, and 56.9%, respectfully; additionally, these compounds exhibit amoebicidal properties as well, whereby the N. fowleri viability was found to be reduced to 27.39%, 26.41%, and 24.13%, respectively. Moreover, the compounds 1c and 1d were found to induce the greatest reductions in amoeba-mediated host cell death, reducing the cell death to 29.8% and 48.5%, respectfully. Additionally, the minimum inhibitory concentrations required to inhibit 50% of N. fowleri growth for the compounds 1e, 1h, and 1f were determined to be 50.96 µM, 60.87 µM, and 48.45 µM, respectfully. Furthermore, the majority of the compounds were found to possess weak cytotoxicity, except for compounds 1o, 1l, 1p, 1m, 1c, 1b, 1zb, 1z, 1y, and 1x, as they were found to possess minimal toxicity. However, studies are needed to determine the effects of selective compounds on both primary as well as immortalized cells. In this study, HeLa cells were employed, since they are an affordable, simplistic model, are widely utilized in biomedical research, and are easy to culture. Future studies are needed to determine the efficacy of the aforementioned compounds against amoeba-mediated host cell damage against the primary brain microvascular endothelial cells that constitute the blood–brain barrier and inhibit drug transport into the brain, as well as in vivo studies to determine whether these compounds can retain their efficacy in animal models of primary amoebic meningoencephalitis due to N. fowleri.

Since the anti-amoebic properties of the compounds against N. fowleri trophozoites were determined, future studies studying the anti-amoebic properties of the compounds against N. fowleri cysts should be conducted. Encystation and excystation assays must be conducted to understand the effects of the compounds in cyst inducement and cyst prevention. Moreover, the mechanism of action of the compounds is unknown. The compounds may be impacting the amoeba membrane or inducing apoptosis; this can be determined through conducting an assay and observing the anti-amoebic effect using an electron microscope.

After conducting a series of in vitro studies, the most promising compounds against N. fowleri should be tested in vivo to proceed further with the lead development process. Several studies have reported animal models of the parasite [35,36], which can be considered by researchers working on anti-Naegleria drug discovery.

4. Materials and Methods

4.1. The Tested Compounds

The series of compounds illustrated in Table 2 were tested in this study.

Table 2.

Structures of the tested target compounds 1azd.

Compound No. Structure
1a graphic file with name antibiotics-11-01515-i001.jpg
1b graphic file with name antibiotics-11-01515-i002.jpg
1c graphic file with name antibiotics-11-01515-i003.jpg
1d graphic file with name antibiotics-11-01515-i004.jpg
1e graphic file with name antibiotics-11-01515-i005.jpg
1f graphic file with name antibiotics-11-01515-i006.jpg
1g graphic file with name antibiotics-11-01515-i007.jpg
1h graphic file with name antibiotics-11-01515-i008.jpg
1i graphic file with name antibiotics-11-01515-i009.jpg
1j graphic file with name antibiotics-11-01515-i010.jpg
1k graphic file with name antibiotics-11-01515-i011.jpg
1l graphic file with name antibiotics-11-01515-i012.jpg
1m graphic file with name antibiotics-11-01515-i013.jpg
1n graphic file with name antibiotics-11-01515-i014.jpg
1o graphic file with name antibiotics-11-01515-i015.jpg
1p graphic file with name antibiotics-11-01515-i016.jpg
1q graphic file with name antibiotics-11-01515-i017.jpg
1r graphic file with name antibiotics-11-01515-i018.jpg
1s graphic file with name antibiotics-11-01515-i019.jpg
1t graphic file with name antibiotics-11-01515-i020.jpg
1u graphic file with name antibiotics-11-01515-i021.jpg
1v graphic file with name antibiotics-11-01515-i022.jpg
1w graphic file with name antibiotics-11-01515-i023.jpg
1x graphic file with name antibiotics-11-01515-i024.jpg
1y graphic file with name antibiotics-11-01515-i025.jpg
1z graphic file with name antibiotics-11-01515-i026.jpg
1za graphic file with name antibiotics-11-01515-i027.jpg
1zb graphic file with name antibiotics-11-01515-i028.jpg
1zc graphic file with name antibiotics-11-01515-i029.jpg
1zd graphic file with name antibiotics-11-01515-i030.jpg

4.2. Henrietta Lacks (HeLa) Cervical Cancer Cells

ATCC CCL-2 Singapore strains of HeLa cells obtained from the American Type Culture Collection (ATCC) were used to maintain N. fowleri and to conduct cytotoxicity and cytopathogenicity assays [12].

Within the complete medium, the cells were grown and cultured. The complete media is made from Roswell Park Memorial Institute medium (RPMI), 10% fetal bovine serum (FBS), 1% minimum essential medium amino acids, 1% L-glutamine, and 1% penicillin–streptomycin (Mungroo, et al., 2020). The flasks of the cells were then placed in a 95% humidifying incubator with 5% CO2 at 37 °C [12].

4.3. Naegleria Fowleri Culture

HB1 ATCC 30174 strains of N. fowleri were placed on HeLa cell (ATCC CCL-2) monolayers [12]. The HeLa cell monolayers served as a food source for the amoeba [12]. In a 95% humidifying incubator with 5% CO2 and 95% at 37 °C, the N. fowleri cultures were maintained. After 48 h, the amoeba was found to have fully consumed the cell monolayers, resulting in an increase in their number, with approximately 5 × 105 being present, from which 95% were in the trophozoite form [11]. Next, the flasks were placed on ice for 15 min to detach the amoebae from the flasks. The media containing amoebae were collected in a 50 mL tube and centrifuged at 2500× g for 10 min at 4 °C. Next, the supernatant was discarded and the pellet was resuspended in 1 mL of RPMI. Finally, the amoebae were enumerated and used for subsequent assays.

4.4. Amoebicidal Assay

Here, 2 × 105 amoebae were treated with different compounds at 50 µM concentrations and placed in a 96-well plate to determine the amoebicidal properties of the compounds [12]. After treatment, the 96-well plate was placed in an incubator containing 95% humidity and 5% CO2 at 37 °C for 24 h.

The following controls were utilized in the assays: amoebae alone with RPMI was the negative control, while amoebae treated with 0.25% SDS was the positive control. Live and dead amoebae were distinguished by the addition of 0.1% methylene blue [12]. The viable amoebae were then counted using a hemocytometer [12].

Furthermore, a student’s t-test with a two-tailed distribution was conducted to determine the statistically significant compounds [12]. Furthermore, the MIC50 values of the compounds were determined using concentrations of 25 µM, 50 µM, and 75 µM [27].

4.5. Cytotoxicity Assay

The HeLa cells were cultured in 96-well plates and treated with different compounds to determine the toxicity of the compounds against the cells. The treated cells were then placed in an incubator with 95% humidity and 5% CO2 at 37 °C for 24 h [12]. Following the overnight incubation period, the cell-free supernatant was gathered and the cytotoxicity of the compounds was determined. This was done through the use of a cytotoxicity detection kit, which measures the quantity of lactate dehydrogenase (LDH) release [37].

The inclusion of positive and negative controls insured accurate results. Serving as the negative control were untreated HeLa cells alone; serving as the positive control were HeLa cells treated with 1% Triton X-100.

Furthermore, by carrying out all of the necessary calculations, the cytotoxic properties of the compounds were determined: (absorbance of media from cells treated with the drugs—absorbance of media from cells of negative control)/(absorbance of media from cells of positive control—absorbance of media from cells of negative control) × 100 [12].

4.6. Cytopathogenicity Assay

Here, 2 × 105 N. fowleri cells were treated with 50 µM of the compounds to determine the amoeba-mediated host cell death. After treatment, the amoebae were incubated for 2 h at 37 °C with 5% CO2 and 95% humidity. Next, the treated N. fowleri cells were placed in 96-well plates containing HeLa cell monolayers overnight [12]. The following day, the supernatant was collected and the cytotoxicity was determined following the method and calculations described earlier [12].

Positive and negative controls were added to the assay to ensure accurate results were obtained. Untreated N. fowleri on HeLa cells served as the negative control, while cells treated with Triton X-100 served as the positive control [12].

4.7. Statistical Analysis

All results presented are descriptive of the mean ± standard error from various independent experiments. Additionally, the statistical significance was determined via a two-tailed distribution t-test [12]. Additionally, to further examine and elaborate the results the p values were determined.

Author Contributions

M.I.E.-G., C.-H.O., and M.S.A.-M. synthesized the target compounds. R.S. and N.A.K. conceived the study amid discussions. M.I.E.-G., N.A.K., A.B., B.Q.S., A.M.A., and H.A. conducted all investigations and data analysis under the supervision of N.A.K., R.S., and M.I.E.-G. Additionally, N.A.K. and M.I.E.-G. wrote the first draft. M.I.E.-G., R.S., and N.A.K. corrected and finalized the manuscript. All authors have read and agreed to the published version of the manuscript.

Data Availability Statement

The datasets generated or analyzed during the current study are available from the corresponding author upon reasonable request.

Conflicts of Interest

All authors declare that they have no conflict of interest.

Funding Statement

This research was funded by the American University of Sharjah and University of Sharjah, United Arab Emirates, grant number 2201110159.

Footnotes

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Pugh J.J., Levy R.A. Naegleria fowleri: Diagnosis, pathophysiology of brain inflammation, and antimicrobial treatments. ACS Chem. Neurosci. 2016;7:1178–1179. doi: 10.1021/acschemneuro.6b00232. [DOI] [PubMed] [Google Scholar]
  • 2.Maciver S.K., Piñero J.E., Lorenzo-Morales J. Is Naegleria fowleri an emerging parasite? Trends Parasitol. 2020;36:19–28. doi: 10.1016/j.pt.2019.10.008. [DOI] [PubMed] [Google Scholar]
  • 3.De Jonckheere J.F. Origin and evolution of the worldwide distributed pathogenic amoeboflagellate Naegleria fowleri. Infect. Genet. Evol. 2011;11:1520–1528. doi: 10.1016/j.meegid.2011.07.023. [DOI] [PubMed] [Google Scholar]
  • 4.Gharpure R., Bliton J., Goodman A., Ali I.K.M., Yoder J., Cope J.R. Epidemiology and clinical characteristics of primary amebic meningoencephalitis caused by Naegleria fowleri: A global review. Clin. Infect. Dis. 2021;73:e19–e27. doi: 10.1093/cid/ciaa520. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Marciano-Cabral F., MacLean R., Mensah A., LaPat-Polasko L. Identification of Naegleria fowleri in domestic water sources by nested PCR. Appl. Environ. Microbiol. 2003;69:5864–5869. doi: 10.1128/AEM.69.10.5864-5869.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Marciano-Cabral F., Cabral G.A. The immune response to Naegleria fowleri amebae and pathogenesis of infection. FEMS Immunol. Med. Microbiol. 2007;51:243–259. doi: 10.1111/j.1574-695X.2007.00332.x. [DOI] [PubMed] [Google Scholar]
  • 7.Siddiqui R., Khamis M., Ibrahim T., Khan N.A. Brain-Eating Amoebae in the United Arab Emirates? ACS Pharmacol. Transl. Sci. 2021;4:1014–1015. doi: 10.1021/acsptsci.1c00003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Matin A., Siddiqui R., Jayasekera S., Khan N.A. Increasing importance of Balamuthia mandrillaris. Clin. Microbiol. Rev. 2008;21:435–448. doi: 10.1128/CMR.00056-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.da Rocha-Azevedo B., Tanowitz H.B., Marciano-Cabral F. Diagnosis of infections caused by pathogenic free-living amoebae. Interdiscip. Perspect. Infect. Dis. 2009;2009:251406. doi: 10.1155/2009/251406. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Siddiqui R., Ali I.K.M., Cope J.R., Khan N.A. Biology and pathogenesis of Naegleria fowleri. Acta Trop. 2016;164:375–394. doi: 10.1016/j.actatropica.2016.09.009. [DOI] [PubMed] [Google Scholar]
  • 11.Rajendran K., Anwar A., Khan N.A., Siddiqui R. Brain-Eating Amoebae: Silver Nanoparticle Conjugation Enhanced Efficacy of Anti-Amoebic Drugs against Naegleria fowleri. ACS Chem. Neurosci. 2017;8:2626–2630. doi: 10.1021/acschemneuro.7b00430. [DOI] [PubMed] [Google Scholar]
  • 12.Mungroo M.R., Anwar A., Khan N.A., Siddiqui R. Gold-Conjugated Curcumin as a Novel Therapeutic Agent against Brain-Eating Amoebae. ACS Omega. 2020;5:12467–12475. doi: 10.1021/acsomega.0c01305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Anwar A., Mungroo M.R., Khan S., Fatima I., Rafique R., Kanwal, Khan K.M., Siddiqui R., Khan N.A. Novel Azoles as Antiparasitic Remedies against Brain-Eating Amoebae. Antibiotics. 2020;9:188. doi: 10.3390/antibiotics9040188. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Khan N.A., Muhammad J.S., Siddiqui R. Brain-eating amoebae: Is killing the parasite our only option to prevent death? Expert Rev. Anti-Infect. Ther. 2021;20:1–2. doi: 10.1080/14787210.2021.1927712. [DOI] [PubMed] [Google Scholar]
  • 15.Siddiqui R., Khan N.A. Contemporary approaches to treat Naegleria fowleri: A patent overview. Pharm. Pat. Anal. 2020;10:99–101. doi: 10.4155/ppa-2020-0023. [DOI] [PubMed] [Google Scholar]
  • 16.Baig A.M. Global warming favors pathogenicity of the brain-eating amoebae. Anti-Infect. Agents. 2019;17:2–3. doi: 10.2174/2211352516999181023142055. [DOI] [Google Scholar]
  • 17.Trabelsi H., Dendana F., Sellami A., Sellami H., Cheikhrouhou F., Neji S., Makni F., Ayadi A. Pathogenic free-living amoebae: Epidemiology and clinical review. Pathol. Biol. 2012;60:399–405. doi: 10.1016/j.patbio.2012.03.002. [DOI] [PubMed] [Google Scholar]
  • 18.Grace E., Asbill S., Virga K. Naegleria fowleri: Pathogenesis, diagnosis, and treatment options. Antimicrob. Agents Chemother. 2015;59:6677–6681. doi: 10.1128/AAC.01293-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Rice C.A., Colon B.L., Chen E., Hull M.V., Kyle D.E. Discovery of repurposing drug candidates for the treatment of diseases caused by pathogenic free-living amoebae. PLoS Negl. Trop. Dis. 2020;14:e0008353. doi: 10.1371/journal.pntd.0008353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Park J.-H., Oh C.-H. Synthesis of new 6-(4-fluorophenyl)-5-(2-substituted pyrimidin-4-yl)imidazo[2,1-b]thiazole derivatives and their antiproliferative activity against melanoma cell line. Bull. Korean Chem. Soc. 2010;31:2854–2860. doi: 10.5012/bkcs.2010.31.10.2854. [DOI] [Google Scholar]
  • 21.Park J.-H., El-Gamal M.I., Lee Y.S., Oh C.-H. New imidazo[2,1-b]thiazole derivatives: Synthesis, in vitro anticancer evaluation, and in silico studies. Eur. J. Med. Chem. 2011;46:5769–5777. doi: 10.1016/j.ejmech.2011.08.024. [DOI] [PubMed] [Google Scholar]
  • 22.Abdel-Maksoud M.S., El-Gamal M.I., Gamal El-Din M.M., Kwak S.-S., Kim H.-I., Oh C.-H. Broad-spectrum antiproliferative activity of a series of 6-(4-fluorophenyl)-5-(2-substituted pyrimidin-4-yl)imidazo[2,1-b]thiazole derivatives. Med. Chem. Res. 2016;25:824–833. doi: 10.1007/s00044-016-1529-7. [DOI] [Google Scholar]
  • 23.Anbar H.S., El-Gamal M.I., Tarazi H., Lee B.S., Jeon H.R., Kwon D., Oh C.-H. Imidazothiazole-based potent inhibitors of V600E-B-RAF kinase with promising anti-melanoma activity: Biological and computational studies. J. Enz. Inhibit. Med. Chem. 2020;35:1712–1726. doi: 10.1080/14756366.2020.1819260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Abdel-Maksoud M.S., El-Gamal M.I., Lee B.S., Gamal El-Din M.M., Jeon H.R., Kwon D., Ammar U.M., Mersal K.I., Ali E.M.H., Lee K.-T., et al. Discovery of New Imidazo[2,1-b]thiazole Derivatives as Potent Pan-RAF Inhibitors with Promising In vitro and In vivo Anti-melanoma Activity. J. Med. Chem. 2021;64:6877–6901. doi: 10.1021/acs.jmedchem.1c00230. [DOI] [PubMed] [Google Scholar]
  • 25.Akbar N., El-Gamal M.I., Saeed B.Q., Oh C.-H., Abdel-Maksoud M.S., Khan N.A., Alharbi A.M., Alfahemi H., Siddiqui R. Antiamoebic activity of imidazothiazole derivatives against opportunistic pathogen Acanthamoeba castellanii. Antibiotic. 2022;11:1183. doi: 10.3390/antibiotics11091183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Biological Evaluation of Medical Devices-Part 5: Tests for In Vitro Cytotoxicity. International Organization for Standardization; Geneva, Switzerland: 2009. [Google Scholar]
  • 27.Akbar N., Siddiqui R., Iqbal M., Khan N.A. Antibacterial activities of selected pure compounds isolated from gut bacteria of animals living in polluted environments. Antibiotics. 2020;9:190. doi: 10.3390/antibiotics9040190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Król-Turmińska K., Olender A. Human infections caused by free-living amoebae. Ann. Agric. Environ. Med. 2017;24:254–260. doi: 10.5604/12321966.1233568. [DOI] [PubMed] [Google Scholar]
  • 29.Ong T.Y.Y., Khan N.A., Siddiqui R. Brain-eating amoebae: Predilection sites in the brain and disease outcome. J. Clin. Microbiol. 2017;55:1989–1997. doi: 10.1128/JCM.02300-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Matanock A., Mehal J.M., Liu L., Blau D.M., Cope J.R. Estimation of undiagnosed Naegleria fowleri primary amebic meningoencephalitis, United States. Emerg. Infect. Dis. 2018;24:162. doi: 10.3201/eid2401.170545. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Taravaud A., Fechtali-Moute Z., Loiseau P.M., Pomel S. Drugs used for the treatment of cerebral and disseminated infections caused by free-living amoebae. Clin. Transl. Sci. 2021;14:791–805. doi: 10.1111/cts.12955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Visvesvara G.S., Moura H., Schuster F.L. Pathogenic and opportunistic free-living amoebae: Acanthamoeba spp., Balamuthia mandrillaris, Naegleria fowleri, and Sappinia diploidea. FEMS Immunol. Med. Microbiol. 2007;50:1–26. doi: 10.1111/j.1574-695X.2007.00232.x. [DOI] [PubMed] [Google Scholar]
  • 33.Rajendran K., Anwar A., Khan N.A., Shah M.R., Siddiqui R. trans-Cinnamic acid conjugated gold nanoparticles as potent therapeutics against brain-eating amoeba Naegleria fowleri. ACS Chem. Neurosci. 2019;10:2692–2696. doi: 10.1021/acschemneuro.9b00111. [DOI] [PubMed] [Google Scholar]
  • 34.Hahn H.J., Abagyan R., Podust L.M., Roy S., Ali I.K.M., Debnath A. HMG-CoA reductase inhibitors as drug leads against Naegleria fowleri. ACS Chem. Neurosci. 2020;11:3089–3096. doi: 10.1021/acschemneuro.0c00428. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Smego R.A., Durack D.T. An experimantal model for Naegleria fowleri-induced primary amebic meningoencephalitis in rabbits. J. Parasitol. 1984;70:78–81. doi: 10.2307/3281928. [DOI] [PubMed] [Google Scholar]
  • 36.Castillo-Ramirez D.A., Carrasco-Yepez M.M., Rodriguez-Mera I.B., Resendiz-Albor A.A., Rosales-Cruz E., Rojas-Hernandez S. A 250-kDa glycoprotein of Naegleria fowleri induces protection and modifies the expression of α4β1 and LFA-1 on T and B lymphocytes in mouse meningitis model. Parasite Immunol. 2021;43:e12882. doi: 10.1111/pim.12882. [DOI] [PubMed] [Google Scholar]
  • 37.Jeyamogan S., Khan N.A., Anwar A., Shah M.R., Siddiqui R. Cytotoxic effects of Benzodioxane, Naphthalene diimide, Porphyrin and Acetamol derivatives on HeLa cells. SAGE Open Med. 2018;6:2050312118781962. doi: 10.1177/2050312118781962. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The datasets generated or analyzed during the current study are available from the corresponding author upon reasonable request.


Articles from Antibiotics are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES